Syndax to price IPO of 4.3 million shares between $13.00 and $15.00

Deutsche Bank and Jefferies to be joint bookrunning managers for deal

By Devika Patel

Knoxville, Tenn., June 5 – Syndax Pharmaceuticals, Inc. will sell 4.3 million common shares in its initial public offering with a 30-day greenshoe of 645,000 additional shares, according to a Form S-1/A filed Thursday with the Securities and Exchange Commission. The deal was announced March 27.

The shares will be sold at a price expected to fall between $13.00 and $15.00 per share.

Deutsche Bank Securities and Jefferies are the joint bookrunning managers. JMP Securities and Wedbush PacGrow Life Sciences are the co-managers.

Proceeds will be used for clinical trials, working capital and general corporate purposes.

The biopharmaceutical company is based in Waltham, Mass. The company intends to list its common stock on the Nasdaq under the symbol “SNDX.”

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.